Evidence map›Paper›PMID 39346901›Full record

ArticleFrontiers in immunology2024

Supplementation with

Husile Alatan, Shan Liang, Yosuke Shimodaira, Xiaoli Wu, Xu Hu, Tao Wang, Jia Luo, Katsunori Iijima, Feng Jin

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Frontiers in microbiology · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Nutrients · 2025
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Husile Alatan *Department of Gastroenterology and Neurology, Akita University Graduate School of Medicine, Akita, Japan.
Shan Liang *Mirai Food Academic Institute of Japan, Akita, Japan.
Yosuke ShimodairaDepartment of Gastroenterology and Neurology, Akita University Graduate School of Medicine, Akita, Japan.
Xiaoli WuKey Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
Xu HuKey Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
Tao WangKey Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
Jia LuoPsychology College, Sichuan Normal University, Chengdu, China.
Katsunori IijimaDepartment of Gastroenterology and Neurology, Akita University Graduate School of Medicine, Akita, Japan.
Feng JinMirai Food Academic Institute of Japan, Akita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Major depressive disorder is a condition involving microbiota-gut-brain axis dysfunction. Increasing research aims to improve depression through gut microbiota regulation, including interventions such as probiotics, prebiotics, and fecal microbiota transplants. However, most research focuses on exogenous depression induced by chronic stress or drugs, with less attention given to endogenous depression. Additionally, research on gut mycobiota in depression is significantly less than that on gut bacteria. Methods: In the present study, Wistar-Kyoto rats were used as an endogenous depression and treatment-resistant depression model, while Wistar rats served as controls. Differences between the two rat strains in behavior, gut bacteria, gut mycobiota, nervous system, endocrine system, immune system, and gut barrier were evaluated. Additionally, the effects of Results: Wistar-Kyoto rats demonstrated increased depressive-like behaviors in the forced swimming test, reduced sucrose preference in the sucrose preference test, and decreased locomotor activity in the open field test. They also exhibited abnormal gut bacteria and mycobiota, characterized by higher bacterial α-diversity but lower fungal α-diversity, along with increased butyrate, L-tyrosine, and L-phenylalanine biosynthesis from bacteria. Furthermore, these rats showed dysfunction in the microbiota-gut-brain axis, evidenced by a hypo-serotonergic system, hyper-noradrenergic system, defective hypothalamic-pituitary-adrenal axis, compromised gut barrier integrity, heightened serum inflammation, and diminished gut immunity. A 1-month Conclusion: The depressive phenotype of Wistar-Kyoto rats is not only attributed to their genetic context but also closely related to their gut microbiota. Abnormal gut microbiota and a dysfunctional microbiota-gut-brain axis play important roles in endogenous depression, just as they do in exogenous depression. Supplementing with probiotics such as

Indexed as

Brain-Gut AxisDepressionDisease Models, AnimalGastrointestinal MicrobiomeLactobacillus helveticusProbioticsRats, Inbred WKYAnimalsBehavior, AnimalMaleRatsRats, Wistarbutyratecorticotropin releasing hormonegut barrierinflammationmicrobiotamycobiotanoradrenalineserotonin

Identifiers

PMID39346901
PMCPMC11428200

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.